Development and validation of a reversed-phase HPLC method for quantification of 1’-acetoxychavicol acetate content in a nanostructured lipid carrier formulation
DOI:
https://doi.org/10.1590/s2175-97902022e20627Keywords:
High-performance liquid chromatography, Validation, 1’-acetoxychavicol acetate, Nanostructured lipid carrier, PhotochemotherapyAbstract
1’-acetoxychavicol acetate (ACA)-loaded nanostructured lipid carriers (NLCs) were formulated for prostate cancer therapy and to determine the optimal therapeutic dose, we developed a rapid, specific, and accurate reversed-phase high-performance liquid chromatography (RP-HPLC) method to quantify the ACA content in NLCs. The method was validated according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines. Chromatographic separation of ACA from the lipid components was performed with an Agilent 1220 Infinity LC system and ultraviolet detector using an Agilent Poroshell C18 column (4.6 x 250.0 mm). The mobile phase consisted of acetonitrile and water (80:20 [v/v]) with a flow rate of 0.8 mL/min in isocratic mode. Linearity of the standard curve was assessed at an ACA concentration range of 5-200 µg/mL, and a 1/x weighted linear regression was adopted for the calibration curve. The calculated limits of detection and quantification were 0.59 µg/mL and 1.79 µg/mL, respectively. The mean percent recovery of ACA was 100.02% (relative SD, 2%), and the coefficients of variation for intraday and interday assays were within the values required by the ICH. We also demonstrated robustness of the method by altering the mobile phase ratio and flow rate. Furthermore, we proved specificity of the method for ACA by comparing chromatograms of the blank NLC and ACA-NLC. Hence, we effectively used this validated method to determine the drug-loading capacity and entrapment efficiency of the NLCs.
Downloads
References
Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29(Suppl 1):S49-S52.
Arshad NM, In LLA, Soh TL, Mohamad NA, Ibrahim H, Awang K, et al. Recombinant human alpha fetoprotein synergistically potentiates the anti-cancer effects of 1′-S-1′-acetoxychavicol acetate when used as a complex against human tumours harbouring AFP-receptors. Oncotarget. 2015;6(18):16151-67.
Awang K, Azmi MN, Aun LI, Aziz AN, Ibrahim H, Nagoor NH. The apoptotic effect of 1’-S-1’-acetoxychavicol acetate from Alpinia conchigera on human cancer cells. Molecules. 2010;15(11):8048-8059.
Baradwaj RG, Rao MV, Kumar TS. Novel purification of 1’-S-1’-Acetoxychavicol acetate from Alpinia galanga and its cytotoxic plus antiproliferative activity in colorectal adenocarcinoma cell line SW480. Biomed Pharmacother. 2017;91:485-493.
Barik BR, Kundu AB, Dey AK. Two phenolic constituents from Alpinia galanga rhizomes. Phytochemistry. 1987;26(7):2126-27.
Batra V, Syed Z, Gill JN, Coburn MA, Adegboyega P, DiGiovanni J, et al. Effects of the tropical ginger compound, 1’-acetoxychavicol acetate, against tumor promotion in K5. Stat3C transgenic mice. J Exp Clin Cancer Res. 2012;31(1):57.
Beloqui A, Solinis MA, Rodriguez-Gascon A, Almeida AJ, Preat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143-61.
Boulanger B, Chiap P, Dewe W, Crommen J, Hubert PH. An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progresses and limitations. J Pharm Biomed Anal. 2003;32(4-5):753-65.
Ferreira M, Chaves LL, Lima SA, Reis S. Optimization of nanostructured lipid carriers loaded with methotrexate: A tool for inflammatory and cancer therapy. Int J Pharm. 2015;492(1-2):65-72.
Fontana MC, Bastos MO, Beck RCR. Development and validation of a fast RP-HPLC method for the determination of clobetasol propionate in topical nanocapsule suspensions. J Chromatogr Sci. 2010;48(8):637-40
Gaikwad VL, Choudhari PB, Bhatia NM, Bhatia MS. Characterization of pharmaceutical nanocarriers: in vitro and in vivo studies. In: Grumezescu AM, editors. Nanomaterials for Drug Delivery and Therapy. Norwich, NY: William Andrew Publishing; 2019. p. 33-58.
Haque AKMM, Leong KH, Lo YL, Awang K, Nagoor NH. In vitro inhibitory mechanisms and molecular docking of 1’-S-1’-acetoxychavicol acetate on human cytochrome P450 enzymes. Phytomedicine. 2017;31:1-9.
ICH. Validation of analytical procedures: text and methodology Q2 (R1). In: International Conference on Harmonisation of Technical Requirements For Registration of Pharmaceuticals for Human Use. Geneva, Switzerland. 2005;11-12.
In LLA, Arshad NM, Ibrahim H, Azmi MN, Awang K, Nagoor NH. 1’-Acetoxychavicol acetate inhibits growth of human oral carcinoma xenograft in mice and potentiates cisplatin effect via proinflammatory microenvironment alterations. BMC Complement Altern Med. 2012;12:179.
Ito K, Nakazato T, Murakami A, Yamato K, Miyakawa Y, Yamada T, et al. Induction of apoptosis in human myeloid leukemic cells by 1′-acetoxychavicol acetate through a mitochondrial-and Fas-mediated dual mechanism. Clin Cancer Res. 2004;10(6):2120-30.
Janssen AM, Scheffer JJ. Acetoxychavicol acetate, an antifungal component of Alpinia galangal. Planta Med.1985;51(6):507-11.
Kaur A, Singh R, Dey CS, Sharma SS, Bhutani KK, Singh IP. Antileishmanial phenylpropanoids from Alpinia galanga (Linn.) Willd. Indian J Exp Biol. 2010;48(3):314-7.
Kondo A, Ohigashi H, Murakami A, Jiwajinda S, Koshimizu K. A potent inhibitor of tumor promoter-induced Epstein-Barr virus activation, 1’-acetoxychavicol acetate from Languas galanga, a traditional Thai condiment. Biosci Biotechnol Biochem.1993;57(8):1344-45.
Lopes CE, Langoski G, Klein T, Ferrari PC, Farago PV. A simple HPLC method for the determination of halcinonide in lipid nanoparticles: Development, validation, encapsulation efficiency, and in vitro drug permeation. Braz J Pharm Sci. 2017;53(2):e15250.
Martins LG, Mainardes RM. Application of a validated HPLC-PDA method for the determination of melatonin content and its release from poly (lactic acid) nanoparticles. J Pharm Anal. 2017;7(6):388-93.
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131-55.
Nakamura Y, Murakami A, Ohto Y, Torikai K, Tanaka T, Ohigashi H. Suppression of tumor promoter-induced oxidative stress and inflammatory responses in mouse skin by a superoxide generation inhibitor 1’-acetoxychavicol acetate. Cancer Res. 1998;58(21):4832-9.
Narukawa M, Koizumi K, Iwasaki Y, Kubota K, Watanabe T. Galangal pungent component, 1’-acetoxychavicol acetate, activates TRPA1. Biosci Biotechnol Biochem . 2010;74(8):1694-6.
Negi LM, Jaggi M, Talegaonkar SA. Logical approach to optimize the nanostructured lipid carrier system of irinotecan: Efficient hybrid design methodology. Nanotechnology. 2013;24(1): 015104.
Niyomkam P, Kaewbumrung S, Kaewnpparat S, Panichayupakaranant P. Antibacterial activity of Thai herbal extracts on acne involved microorganism. Pharm Biol. 2010;48(4):375-80.
Pathak Y. Recent developments in nanoparticulate drug delivery systems. In: Pathak Y, Thassu D, editors. Drug Delivery Nanoparticles Formulation and Characterization (1st ed.). Boca Raton, FL: CRC Press; 2009. p. 1-7.
Pecchio M, Salman H, Irache JM, Renedo MJ, Dios-Viéitez MC. Development and validation of a HPLC method for the determination of cyclosporine a in new bioadhesive nanoparticles for oral administration. Indian J Pharm Sci. 2014;76(2):132-137.
Savadkouhi MB, Vahidi H, Ayatollahi AM, Hooshfar S, Kobarfard F. RP-HPLC method development and validation for determination of eptifibatide acetate in bulk drug substance and pharmaceutical dosage forms. Iran J Pharm Res. 2017;16(2):490-497.
Severino P, Santana MH, Souto EB. Optimizing SLN and NLC by 2(2) full factorial design: Effect of homogenization technique. Mater Sci Eng C Mater Biol Appl. 2012;32(6):1375-9.
Sonawane SS, Chhajed SS, Attar SS, Kshirsagar SJ. An approach to select linear regression model in bioanalytical method validation. J Anal Sci Technol. 2019;10:1-7.
Tanaka T, Kawabata K, Kakumoto M, Makita H, Matsunaga K, Mori H, et al. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor, 1’-acetoxychavicol acetate. Jpn JCancer Res .1997;88(9):821-30.
Tanaka T, Makita H, Kawamori T, Kawabata K, Mori H, Murakami A, et al. A xanthine oxidase inhibitor 1’-acetoxychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis. 1997;18(5):1113-8.
Yang X, Eilerman RG. Pungent principal of Alpinia galangal (L.) swartz and its applications. J Agric Food Chem.1999;47(4):1657-62.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
